Current Report Filing (8-k)
June 28 2017 - 6:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
June 26, 2017
Sevion Therapeutics, Inc.
(Exact Name of Registrant as Specified in
Charter)
Delaware
|
001-31326
|
84-1368850
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
10210 Campus Point Drive, Suite 150, San Diego, CA
|
92121
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
858-909-0749
|
(Registrant's telephone number,
including area code)
|
|
___________________
Not applicable
_____________________
(Former Name or Former Address, if Changed
Since Last Report)
|
|
Check the appropriate box below if the Form 8-K is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425).
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12).
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 7.01 Regulation FD Disclosure
On June 26, 2017, Sevion Therapeutics, Inc.
issued a press release announcing the closing of a $6 million investment into Eloxx Pharmaceuticals, Ltd. The Company is furnishing
a copy of the press release, which is attached hereto as Exhibit 99.1.
In accordance with General Instructions
B.2 and B.6 of Form 8-K, the information included in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 attached
hereto), shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by
reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, except as shall
be expressly set forth by specific reference in such a filing.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number
|
Description
|
99.1
|
Press Release dated June 26, 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Sevion Therapeutics, Inc.
|
Dated: June 27, 2017
|
|
|
|
|
By:
|
/s/ David Rector
|
|
|
David Rector
|
|
|
Chief Executive Officer
|
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Sep 2023 to Sep 2024